Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject...
Pharmaceutical
Todos Medical Announces BioFuture™ NYC 2022 Presentation
New York, NY, and Tel Aviv, ISRAEL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB:...
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational...
Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition
New data from clinical trials of TT11 and TT11X to be featured in two oral podium presentations and a poster...
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforce Hemlibra’s efficacy and safety in infants with severe haemophilia A without...
ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047
LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December 10, 2022SAN DIEGO, Nov. 03,...
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignanciesSAN FRANCISCO,...
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
Clinical Presentations to Include Initial Clinical Data of FT576 BCMA-targeted CAR NK Cell Product Candidate for Multiple Myeloma and FT819...
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating...
Imago BioSciences Announces Oral Data Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical...
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition
– Long-term Data for PYRUKYND® (mitapivat) in Adults with Pyruvate Kinase (PK) Deficiency and Adults with Thalassemia Demonstrate Sustained Improvement...
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage...
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30...
Acquisition Has Love Pharma’s Naltrexone on NIH Shortlist to Address Unmet Medical Need—Treatment for Long Covid
NEW YORK, NY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0), an international mental health...
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief...
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
BURNABY, British Columbia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the...
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
Las Vegas, Nevada, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the...